Luca Licata

PARP Inhibitors for Breast Cancer Treatment

Stefania Morganti, Antonio Marra, Carmine De Angelis et al. · JAMA Oncology · 2024 · 76 citations · Full text

Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak

Giulia Viale, Luca Licata, Lorenzo Sica et al. · The Oncologist · 2020 · 37 citations · Full text

Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response

Carlo Bosi, Áron Bartha, Barbara Galbardi et al. · European Journal of Cancer · 2023 · 36 citations · Full text

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Marina Elena Cazzaniga, Mario Airoldi, Valentina Arcangeli et al. · The Breast · 2017 · 23 citations · Full text

Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience

Raffaella Palumbo, Federico Sottotetti, Erica Quaquarini et al. · Therapeutic Advances in Medical Oncology · 2019 · 18 citations · Full text